Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls
Hendrik Gremmels, Martin Teraa, Paul Ha Quax, Krista den Ouden, Joost O Fledderus, Marianne C Verhaar, Hendrik Gremmels, Martin Teraa, Paul Ha Quax, Krista den Ouden, Joost O Fledderus, Marianne C Verhaar
Abstract
Critical limb ischemia (CLI) is often poorly treatable by conventional management and alternatives such as autologous cell therapy are increasingly investigated. Whereas previous studies showed a substantial impairment of neovascularization capacity in primary bone-marrow (BM) isolates from patients, little is known about dysfunction in patient-derived BM mesenchymal stromal cells (MSCs). In this study, we have compared CLI-MSCs to healthy controls using gene expression profiling and functional assays for differentiation, senescence and in vitro and in vivo pro-angiogenic ability. Whereas no differentially expressed genes were found and adipogenic and osteogenic differentiation did not significantly differ between groups, chondrogenic differentiation was impaired in CLI-MSCs, potentially as a consequence of increased senescence. Migration experiments showed no differences in growth factor sensitivity and secretion between CLI- and control MSCs. In a murine hind-limb ischemia model, recovery of perfusion was enhanced in MSC-treated mice compared to vehicle controls (71 ± 24% versus 44 ± 11%; P < 1 × 10(-6)). CLI-MSC- and control-MSC-treated animals showed nearly identical amounts of reperfusion (ratio CLI:Control = 0.98, 95% CI = 0.82-1.14), meeting our criteria for statistical equivalence. The neovascularization capacity of MSCs derived from CLI-patients is not compromised and equivalent to that of control MSCs, suggesting that autologous MSCs are suitable for cell therapy in CLI patients.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4429738/bin/mt2014161f1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4429738/bin/mt2014161f2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4429738/bin/mt2014161f3.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4429738/bin/mt2014161f4.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4429738/bin/mt2014161f5.jpg)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4429738/bin/mt2014161f6.jpg)
Source: PubMed